Sativex Clinical Review: Typically 8-12 Sprays Daily, Effective for MS Spasticity and Neuropathic Pain
Clinical development of Sativex showed patients typically self-titrate to 8-12 sprays per day (22-32 mg THC, 20-30 mg CBD), with positive placebo-controlled trial results for MS spasticity and neuropathic pain, leading to Canadian approval.
Quick Facts
What This Study Found
This review covered the clinical development of Sativex, one of the first cannabis-based medicines approved through conventional pharmaceutical pathways. As an oromucosal spray allowing flexible, individualized dosing, patients typically self-titrate to approximately 8-12 sprays per day.
At this dosing, patients receive approximately 22-32 mg THC and 20-30 mg CBD daily. Clinical development focused on MS symptoms (spasticity and neuropathic pain) and neuropathic pain from other causes.
Positive results from placebo-controlled trials demonstrated efficacy and tolerability as add-on therapy for these conditions. Sativex had been approved in Canada for neuropathic pain due to MS, with further approvals expected for spasticity and broader neuropathic pain indications based on ongoing studies.
Key Numbers
Each spray: 2.7 mg THC + 2.5 mg CBD. Typical daily dose: 8-12 sprays. Daily THC: approximately 22-32 mg. Daily CBD: approximately 20-30 mg. Approved in Canada for MS neuropathic pain.
How They Did This
Clinical review of the Sativex development program, covering pharmacology, dosing, clinical trial results, and regulatory status. Focused on placebo-controlled trials for MS symptoms and neuropathic pain.
Why This Research Matters
The self-titration approach to dosing, where patients adjust their own dose based on response and tolerability, became a model for other cannabis-based medicines. The typical daily dose range provides useful reference points for clinical practice.
The Bigger Picture
Sativex's development demonstrated that cannabis-based medicines could successfully navigate pharmaceutical regulatory processes. The self-titration dosing model acknowledged the wide variability in individual responses to cannabinoids, a challenge that continues to affect cannabis medicine prescribing.
What This Study Doesn't Tell Us
This review is from the manufacturer's perspective and focuses on positive results. The self-titration dosing approach means controlled dosing comparisons are difficult. Long-term safety data beyond the trial periods was limited.
Questions This Raises
- ?Does the self-titration approach lead to optimal dosing, or do some patients under- or over-dose?
- ?How does Sativex compare to other neuropathic pain treatments in terms of efficacy?
Trust & Context
- Key Stat:
- Patients self-titrate to 8-12 sprays daily, receiving approximately 22-32 mg THC and 20-30 mg CBD
- Evidence Grade:
- Clinical review of controlled trials. Provides useful dosing and efficacy information from the pharmaceutical development program.
- Study Age:
- Published in 2006. Sativex has since been approved in over 25 countries and extensive real-world dosing data is now available.
- Original Title:
- Sativex: clinical efficacy and tolerability in the treatment of symptoms of multiple sclerosis and neuropathic pain.
- Published In:
- Expert opinion on pharmacotherapy, 7(5), 607-15 (2006)
- Authors:
- Barnes, Michael Philip(2)
- Database ID:
- RTHC-00214
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
How much THC and CBD is in each Sativex spray?
Each spray delivers 2.7 mg of THC and 2.5 mg of CBD. Patients typically use 8-12 sprays per day, resulting in approximately 22-32 mg THC and 20-30 mg CBD daily, though the flexible dosing allows individual adjustment.
What conditions has Sativex been approved for?
At the time of this 2006 review, Sativex was approved in Canada for neuropathic pain in MS. It has since been approved in over 25 countries, primarily for MS-related spasticity.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
Cite This Study
https://rethinkthc.com/research/RTHC-00214APA
Barnes, Michael Philip. (2006). Sativex: clinical efficacy and tolerability in the treatment of symptoms of multiple sclerosis and neuropathic pain.. Expert opinion on pharmacotherapy, 7(5), 607-15.
MLA
Barnes, Michael Philip. "Sativex: clinical efficacy and tolerability in the treatment of symptoms of multiple sclerosis and neuropathic pain.." Expert opinion on pharmacotherapy, 2006.
RethinkTHC
RethinkTHC Research Database. "Sativex: clinical efficacy and tolerability in the treatment..." RTHC-00214. Retrieved from https://rethinkthc.com/research/barnes-2006-sativex-clinical-efficacy-and
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.